Real-life experience of patients with sarcomatoid renal cell carcinoma: a multicenter retrospective study

Basit Öğe Kaydı
dc.contributor.authorAlmuradova, Elvina
dc.contributor.authorBasoglu, Tugba
dc.contributor.authorNayir, Erdinc
dc.contributor.authorBayram, Ertugrul
dc.contributor.authorPaydas, Semra
dc.contributor.authorGokmen, Ivo
dc.contributor.authorKarakaya, Serdar
dc.date.accessioned2024-02-23T14:38:00Z
dc.date.available2024-02-23T14:38:00Z
dc.date.issued2023
dc.departmentNEÜen_US
dc.description.abstractSarcomatoid renal cell carcinoma (sRCC) is a rare variant of renal cell carcinoma (RCC) and is associated with a poor prognosis. We reviewed the outcomes of patients from oncology centers in Turkey. Our aim is to share our real-life experi-ence and to contribute to the literature. The demographic and clinical features, treatment, and survival outcomes of 148 patients with sRCC were analyzed. The median age at the time of diagnosis was 58 years (range: 19-83 years). Most patients (62.8%) had clear-cell histology. Most patients were in the intermediate Memorial Sloan-Kettering Cancer Center (MSKCC) risk group (67.6%) and were stage 4 at the time of diagnosis (63.5%). The most common sites of metastasis were the lung (60.1%), lymph nodes (47.3%), and bone (35.8%). The patients received a median of two lines (range: 0-6) of treatment. The most common side effects were fatigue, hematological side effects, hypertension, and hypothyroidism. The median follow-up was 20.9 months (range: 1-162 months). The median overall survival (OS) was 30.8 months (95% confidence interval: 24.9-36.7 months). In multivariate analysis, high MSKCC scores, sarcomatoid differentiation rates >50%, having stage 4 disease, and having lung metastasis at the time of diagnosis were independent factors for poor prognosis affecting OS. No difference was observed between patients who received tyrosine kinase inhibitor (TKI) as the first or second-line treatments. Similarly, no difference between TKI and immunotherapy as the second-line treatment. In conclusion, sRCC is a rare variant of RCC with a poor prognosis and response to treatment. Larger-scale prospective studies are needed to define an optimal treatment approach for longer survival in this aggressive variant.en_US
dc.description.sponsorshipMediterranean Oncology Association (Akdeniz Onkoloji Dernegi-AOD)en_US
dc.description.sponsorshipFinancial support was received from the Mediterranean Oncology Association (Akdeniz Onkoloji Dernegi-AOD) for the statistical analysis of the study.en_US
dc.identifier.doi10.4149/neo_2022_221004N984
dc.identifier.endpage165en_US
dc.identifier.issn0028-2685
dc.identifier.issn1338-4317
dc.identifier.issue1en_US
dc.identifier.pmid36620878en_US
dc.identifier.scopus2-s2.0-85150311495en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage158en_US
dc.identifier.urihttps://doi.org/10.4149/neo_2022_221004N984
dc.identifier.urihttps://hdl.handle.net/20.500.12452/16327
dc.identifier.volume70en_US
dc.identifier.wosWOS:000978110900004en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherAepress Sroen_US
dc.relation.ispartofNeoplasmaen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectRenal Cell Carcinomaen_US
dc.subjectSarcomatoiden_US
dc.subjectMetastaticen_US
dc.subjectTargeted Therapyen_US
dc.titleReal-life experience of patients with sarcomatoid renal cell carcinoma: a multicenter retrospective studyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu